Portal vein thrombosis and outcomes for pediatric liver transplant candidates and recipients in the United States

Seth A. Waits, Brandon M. Wojcik, Shijie Cai, Amit K. Mathur, Michael J. Englesbe – 8 July 2011 – The effect of occlusive portal vein thrombosis (PVT) on the mortality of pediatric liver transplant candidates and recipients is poorly defined. Using standard multivariate techniques, we studied the relationship between PVT and waiting‐list and posttransplant survival rates with data from the Scientific Registry of Transplant Recipients (September 2001 to December 2007). In all, 5087 liver transplant candidates and 3630 liver transplant recipients were evaluated during the period.

Genes inducing iPS phenotype play a role in hepatocyte survival and proliferation in vitro and liver regeneration in vivo

Vishakha S. Bhave, Shirish Paranjpe, William C. Bowen, Shashikiran Donthamsetty, Aaron W. Bell, Jaspal S. Khillan, George K. Michalopoulos – 7 July 2011 – Reprogramming factors have been used to induce pluripotent stem cells as an alternative to somatic cell nuclear transfer technology in studies targeting disease models and regenerative medicine. The neuronal repressor RE‐1 silencing transcription factor (REST) maintains self‐renewal and pluripotency in mouse embryonic stem cells by maintaining the expression of Oct3/4, Nanog, and cMyc.

Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis

Masanobu Tsuda, Yoko M. Ambrosini, Weici Zhang, Guo‐Xiang Yang, Yugo Ando, Guanghua Rong, Koichi Tsuneyama, Kosuke Sumida, Shinji Shimoda, Christopher L. Bowlus, Patrick S.C. Leung, Xiao‐Song He, Ross L. Coppel, Aftab A. Ansari, Zhe‐Xiong Lian, M. Eric Gershwin – 6 July 2011 – In primary biliary cirrhosis (PBC), patients develop a multilineage response to a highly restricted peptide of the E2 component of pyruvate dehydrogenase (PDC‐E2) involving autoantibody and autoreactive cluster of differentiation (CD)4+ and CD8+ T‐cell responses.

Gankyrin‐mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells

Wen Sun, Jin Ding, Kun Wu, Bei‐Fang Ning, Wen Wen, Han‐Yong Sun, Tao Han, Lei Huang, Li‐Wei Dong, Wen Yang, Xing Deng, Zhong Li, Meng‐Chao Wu, Gen‐Sheng Feng, Wei‐Fen Xie, Hong‐Yang Wang – 6 July 2011 – Gankyrin is a critical oncoprotein overexpressed in human hepatocellular carcinoma (HCC). However, the mechanism underlying gankyrin‐mediated hepatocarcinogenesis remains elusive. Herein, we provide evidence that gankyrin expression was progressively elevated in liver fibrosis, cirrhosis, and HCC.

Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes

Budhaditya Mazumdar, Arup Banerjee, Keith Meyer, Ranjit Ray – 6 July 2011 – Our previous studies demonstrated that hepatitis C virus (HCV) envelope glycoproteins 1 and 2 (E1 and E2) display distinct reactivity to different cell‐surface molecules. In this study, we characterized the interaction of E1 and E2 with apolipoproteins in facilitating virus entry.

Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy

Chiao‐Fang Teng, Han‐Chieh Wu, Hung‐Wen Tsai, Her‐Shyong Shiah, Wenya Huang, Ih‐Jen Su – 6 July 2011 – Ground glass hepatocytes (GGHs) harboring hepatitis B virus (HBV) pre‐S mutants have been recognized as precursor lesions of hepatocellular carcinoma (HCC). Previously, we observed the activation of mammalian target of rapamycin (mTOR) in GGHs and HCCs, together with a decreased expression of HBV surface antigen (HBsAg) in HCC tissues. It is, therefore, hypothesized that the activation of mTOR during HBV tumorigenesis may potentially down‐regulate HBsAg expression.

Subscribe to